Joshua Ruch has served on has served on the Board of Directors at GeneDx (formerly Sema4) since November 2017.
Currently, Joshua is also co-founder and CEO of Rho Capital Partners, an investment and venture capital management company based in New York and Palo Alto. Rho’s activities include investing in information technology, communications, new media, health care, and energy technology, as well as investing in private equity funds and public securities. Before co-founding Rho in 1981, Joshua worked as an investment banker at Salomon Brothers in New York.
In addition to GeneDx, Joshua currently serves as a member of the Board of Directors for Enerkem, Fractal Systems, CloudPay, Code Ocean, and Laer.ai. He is also a trustee of the Mount Sinai Health System, Carnegie Hall and the National Humanities Center, and is a member of the Board of Governors of the Technion – Israel Institute of Technology.
Joshua received an MBA from the Harvard Business School and a BSc in electrical engineering from The Technion in Haifa, Israel. He was born in Belgium and grew up in South Africa. Joshua met his wife, Julia, at The Technion and they have three sons and five grandchildren.
What is Joshua Ruch's net worth?
The estimated net worth of Joshua Ruch is at least $1.19 million as of November 24th, 2025. Ruch owns 11,941 shares of GeneDx stock worth more than $1,190,279 as of January 20th. This net worth estimate does not reflect any other assets that Ruch may own. Learn More about Joshua Ruch's net worth.
How do I contact Joshua Ruch?
Has Joshua Ruch been buying or selling shares of GeneDx?
Joshua Ruch has not been actively trading shares of GeneDx during the past quarter. Most recently, Joshua Ruch sold 38,000 shares of the business's stock in a transaction on Monday, November 24th. The shares were sold at an average price of $160.37, for a transaction totalling $6,094,060.00. Following the completion of the sale, the director now directly owns 11,941 shares of the company's stock, valued at $1,914,978.17. Learn More on Joshua Ruch's trading history.
Who are GeneDx's active insiders?
GeneDx's insider roster includes Shawn Assad (CAO), Daniel Clark (General Counsel), James Coffin (COO), Kevin Feeley (CFO), Keith Meister (Director), Richard Pfenniger, Jr. (Director), Richard Pfenniger, Jr. (Director), Anthony Prentice (Insider), Isaac Ro (CFO), Joshua Ruch (Director), Jason Ryan (Chairman of the Board), Eric Schadt (CEO), and Katherine Stueland (CEO). Learn More on GeneDx's active insiders.
Are insiders buying or selling shares of GeneDx?
In the last year, GeneDx insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $5,601,000.00. In the last year, insiders at the sold shares 34 times. They sold a total of 777,725 shares worth more than $91,841,370.36. The most recent insider tranaction occured on December, 16th when CFO Kevin Feeley sold 3,855 shares worth more than $554,618.85. Insiders at GeneDx own 29.6% of the company.
Learn More about insider trades at GeneDx. Information on this page was last updated on 12/16/2025.
